| Full text | |
| Author(s): |
Lidianne N. Monteiro
[1]
;
Breno S. Salgado
[2]
;
Deilson E. Oliveira
[3]
;
Luis G. Rivera-Calderon
[4]
;
Luis M. Montoya-Flórez
[5]
;
Paula Sanctis
[6]
;
Noeme S. Rocha
[7]
Total Authors: 7
|
| Affiliation: | [1] Faculdade Multivix. Consultoria Diagnóstica em Patologia Veterinária - Brasil
[2] Universidade Federal do Espírito Santo. Faculdade de Medicina Veterinária - Brasil
[3] Universidade Estadual Paulista “Júlio de Mesquita Filho”. Faculdade de Medicina - Brasil
[4] Universidad Antonio Nariño. Facultad de Medicina Veterinaria - Colômbia
[5] Universidad Antonio Nariño. Facultad de Medicina Veterinaria - Colômbia
[6] Universidade Estadual Paulista “Júlio de Mesquita Filho”. Faculdade de Medicina Veterinária e Zootecnia. Departamento de Clinica Veterinária - Brasil
[7] Universidade Estadual Paulista “Júlio de Mesquita Filho”. Faculdade de Medicina Veterinária e Zootecnia. Departamento de Clinica Veterinária - Brasil
Total Affiliations: 7
|
| Document type: | Journal article |
| Source: | Pesquisa Veterinária Brasileira; v. 40, n. 3, p. 210-219, 2020-05-29. |
| Abstract | |
ABSTRACT: Osteopontin is a glycophosphoprotein implicated in different physiologic and pathologic processes and is known to be involved in progression and metastasis of various cancers in humans, but this relation is still little explored in the veterinary. The aim was to evaluate the expression of osteopontin in canine mammary carcinomas and its relation with well-established canine mammary tumor biomarkers. For that, expression of OPN, EGFR, HER2, and c-Kit were evaluated along with Ki67 rate in 43 mammary carcinomas. Osteopontin was demonstrated to be expressed by neoplastic epithelial cells in all carcinomas as well as in stromal cells from the tumor microenvironment. Relation between high osteopontin expression and EGFR positivity (P<0.001) and HER2 overexpression (P=0.012) was demonstrated. In conclusion, high OPN expression seems to be related to poor prognosis and MAPK pathway activation, given the association with EGFR and HER2, members of the MAPK signaling pathway. (AU) | |
| FAPESP's process: | 10/51596-2 - S100A4 and osteopontin immunoexpression evaluation in canine spontaneous mammary carcinomas |
| Grantee: | Noeme Sousa Rocha |
| Support Opportunities: | Regular Research Grants |